For the year ending 2025-12-31, OPRX had $9,985K increase in cash & cash equivalents over the period. $18,657K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 5,132 |
| Depreciation and amortization | 4,327 |
| Impairment charges | 368 |
| Bad debt expense | 0 |
| Stock-based compensation | 6,962 |
| Amortization of debt issuance costs | 1,110 |
| Accounts receivable | -460 |
| Prepaid expenses and other assets | 467 |
| Accounts payable | -520 |
| Revenue share payable | -1,967 |
| Accrued expenses and other liabilities | 3,374 |
| Operating lease liabilities | 12 |
| Taxes receivable and payable | -1,070 |
| Deferred tax liabilities | -1,214 |
| Deferred loan fees | 250 |
| Deferred revenue | 30 |
| Net cash provided by operating activities | 18,715 |
| Purchases of property and equipment | 58 |
| Capitalized software development costs | 126 |
| Net cash provided by (used in) investing activities | 68 |
| Repayment of long-term debt | 8,000 |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | 1,150 |
| Proceeds from exercise of stock options, net of cash paid for withholding taxes | 352 |
| Net cash used in financing activities | -8,798 |
| Net increase (decrease) in cash and cash equivalents | 9,985 |
| Cash and cash equivalents beginning of period | 13,380 |
| Cash and cash equivalents end of period | 23,365 |
OptimizeRx Corp (OPRX)
OptimizeRx Corp (OPRX)